Selected Publications:
O'Hara MH, Stashwick C, Plesa G, Tanyi JL: Overcoming barriers of car T-cell therapy in patients with mesothelin-expressing cancers. Immunotherapy 9(9):767-80 : 2017.
Yang L, Zhang Y, Shan W, Hu Z, Yuan J, Pi J, Wang Y, Fan L, Tang Z, Li C, Hu X, Tanyi JL, Fan Y, Huang Q, Montone K, Dang CV, Zhang L: Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition. Sci Transl Med 9(400) : 2017.
Tanyi JL, Stashwick C, Plesa G, Morgan MA, Porter D, Maus MV, June CH: Possible compartmental cytokine release syndrome in a patient with recurrent ovarian cancer after treatment with Mesothelin-targeted CAR-T cells. J Immunother 40(3):104-10 : 2017.
Randall L, Wenham RN, Dowdy SC, Low P, Tanyi JL: A Phase 2, Single-Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer. SGO 48th Annual Meeting on Women's Cancer. Scientific Plenary Session, Annual Meeting, National Harbor, MD, : 2017.
George E, Kim H, Krepler C, Wenz B, Makvandi M, Tanyi JL, Brown E, Zhang R, Brafford P, Jean S, Mach RH, Lu Y, Mills GB, Herlyn M, Morgan M, Zhang X, Soslow R, Drapkin R, Johnson N, Zheng Y, Cotsarelis G, Nathanson KL, Simpkins F: A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers. JCI Insight 2(1):e89760 : 2017.
Tayni JL, Cory L, DeJesus E, Keating J, Predina J, Nie S, Desphande C, Low P, Singhal S: Intraoperative molecular imaging can identify sub-centimeter perioneal implants during ovarian cancer cytoreductive surgery. Eur J Gynaecol Oncol 38(4):589-95 : 2016.
Santoiemma PP, Reyes C, Wang LP, McLane MW, Feldman MD, Tanyi JL, Powell DJ Jr: Systematic evaluation of multiple immune markers reveals prognostic factors in ovarian cancer. Gynecol Oncol 143(1):120-7 : 2016.
Tanyi JL, Haas AR, Beatty GB, Stashwick CJ, O'Hara MH, Morgan MA, Porter DL, Melenhorst JJ, Plesa G, Lacey SF, June CH: Anti-mesothelin chimeric antigen receptor T cells in patients with epithelial ovarian cancer (suppl; abstr 5511). Oral presentation, Leveraging the Immuno-Molecular Landscape of Gynecologic Cancers ASCO Annual Meeting, Chicago, IL, J Clin Oncol 34 : 2016.
Haas RA, Plesa G, Torigian D, Moon E, O’Hara M, Beatty G, Tanyi JL, Nelson A, Kerr N, Lacey S, Melenhorst J, Albelda SA, June C: Phase I trial of lentiviral CART-meso cells in progressive malignant pleural mesothelioma (MPM). Poster, International Mesothelioma Interest Group Annual Meeting. Birmingham, UK, : 2016.
Jean S, Li J, Katsaros D, Wubbenhorst B, Maxwell KN, Fishbein L, McLane MW, Benedetto C, Canuto EM, Mitra N, Zhang L, Nathanson KL, Tanyi JL: Paclitaxel is necessary for improved survival in epithelial ovarian cancers with homologous recombination gene mutations. Oncotarget 7(30):48577-585 : 2016.